Physician profile
Michael E Williams
NPI 1295706430
$20,788.57
in general payments reported to CMS, 2019-2025
43 companies · $2,542 in 2025
The $2,542 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,160 · 2020: $1,978 · 2021: $2,810 · 2022: $2,076 · 2023: $2,534 · 2024: $2,689 · 2025: $2,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,459 · Consulting Fee: $200 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,459.32 |
| Consulting Fee | $200.00 |
| Education | $105.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,748.51 | 2019-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,334.09 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,560.98 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $1,444.19 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,335.93 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $886.70 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $712.17 | 2019-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $626.18 | 2021-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $561.85 | 2019-2025 | Trintellix |
| Corium, LLC | $540.29 | 2021-2025 | Azstarys |
| Alkermes, INC. | $496.97 | 2019-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $319.22 | 2021-2025 | Qelbree, Qelbree |
| Merck Sharp & Dohme LLC | $307.21 | 2019-2023 | Belsomra |
| Axsome Therapeutics, INC. | $294.27 | 2022-2025 | Auvelity |
| Allergan, INC. | $284.83 | 2019-2020 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.